Hypothermia for Severe TBI, RAS Inhibitors After TAVR, OAC-PPI Therapy and UGIB, and more

JAMA Editor’s Summary

Hypothermia for Severe TBI, RAS Inhibitors After TAVR, OAC-PPI Therapy and UGIB, and more

Editor's Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the December 04, 2018 issue

December 4, 2018

Listen on your favorite player Take me to this show’s page

Newer →

Vitamin D Receptor Agonists for Hemodialysis Patients, Titin Los-of-Function Variants and Atrial Fibrillation, COIs as Research Misconduct, and more

← Older

ICU Decontamination Strategies, High-Flow Nasal Oxygen for Respiratory Failure, Child Maltreatment Screening Guidelines, and more

Facebook Twitter Buffer LinkedIn WhatsApp

Hypothermia for Severe TBI, RAS Inhibitors After TAVR, OAC-PPI Therapy and UGIB, and more

Editor’s Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the December 04, 2018 issue

Listen on your favorite player

New to Podcasts? It's easy to get started!

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Join Our Newsletter

We gratefully acknowledge the many organizations that have generously supported our podcasts and platform.

Network Sponsors and Advertisers

Event and Media Partners

00:00

00:00